Article Text

Download PDFPDF

Proteomics approaches towards early detection and diagnosis of ovarian cancer
  1. Ali Tiss1,
  2. John Timms2,
  3. Usha Menon2,
  4. Alex Gammerman3 and
  5. Rainer Cramer4
  1. Aff1 Dasman Institute, Biochemistry & Molecular Biology UnitDasman Institute Kuwait City Kuwait
  2. Aff2 grid.83440.3b0000000121901201EGA Institute for Women’s Health, Proteomics UnitUniversity College London London UK
  3. Aff3 grid.4464.20000000121612573Royal Holloway University of London, Computer Learning Research Centre, Royal HollowayUniversity of London Egham UK
  4. Aff4 grid.9435.b0000000404579566University of Reading, Department of ChemistryUniversity of Reading Reading UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Early stage detection of cancer is the key to provide a better outcome for therapeutic intervention. Proteomic technologies hold recently great promise in the search of new clinical biomarkers for the early detection and diagnosis of cancer or for the development of new vaccines.

In this perspective, we will present our recent work in improving early diagnosis of ovarian cancer (OC) by combining MS analysis of serum peptidome with data collected over a period of 7 years from the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Using 295 patients with OC, 290 with benign neoplasm, and 2236 postmenopausal healthy controls, our results showed that OC could be accurately predicted up to 15 months before its clinical diagnosis, based a combination of two MS peaks with CA125 clinical test. An overall sensitivity of 94.8% (96.6% specificity) was obtained when comparing malignancies versus healthy postmenopausal controls. High classification accuracies were also obtained for early-stage cancers (93.5% sensitivity). MS discriminatory peaks were identified as connective tissue-activating peptide III (CTAPIII) and platelet factor 4 (PF4), platelet-derived chemokines, suggesting a link between platelet function and tumour development. Those markers might be promising for clinical use in cancer early detection and treatment.